Navigation Links
Study suggests antibiotic may prevent dreaded brain fever
Date:2/19/2008

Two researchers from National Brain Research Center (NBRC) suggest that a common antibiotic called minocycline may prevent children from death due to Japanese encephalitis (JE), or commonly known as brain fever. Japanese Encephalitis virus is the causative agent for JE. Although there is no consolidated official figure for JE cases in India, a rough estimate would indicate a few thousands fatalities every year. The team found that minocycline, an USFDA approved drug, often used to treat acne, limits the death by reducing the microglial activation, neuronal death as well as viral replication. Microglia are cells that act as the "cleanup crew" for the Central Nervous System (CNS). They destroy damaged cells by releasing toxins and engulfing them. Should they become activated and release their toxins in the CNS, the toxins will kill the healthy neurons critical for normal function of brain.

Our studies in mice suggest that this antibiotic may be a strong candidate for further consideration as a therapeutic drug in patients with JE said Anirban Basu, PhD, Staff Scientist and senior author of this work from NBRC, Manesar, Haryana. The study titled Minocycline neuroprotects, reduces microglial activation, inhibits caspase-3 induction, and viral replication following Japanese Encephalitis will be published in the future issue of Journal of Neurochemistry (www.blackwell-synergy.com/loi/jnc), a journal of the International Society for Neurochemistry. Previous studies from the same group have shown that following JE there was an increased production of cytokines, proteins that cause inflammation of the brain as well as death of neurons. This study goes a step further to show that minocycline is helpful in reducing the level of cytokines and neuronal death following JE. The major finding in this study is that treatment with minocycline provides a complete protection against experimental JE. Minocyclines neuroprotective action is associated with marked decrease in 1) neuronal death, 2) microgliosis and production of cytokine and 3) viral titre. Furthermore, treatment with minocycline also improves the behavioral outcome following JE.

The most recent outbreak in Uttar Pradesh (concentrated in and around Gorakhpur belt, August-September, 2005) left behind more than one thousand dead, mostly children below 15 years of age Dr Basu said. Vaccine made by Central Research Institute (CRI), Kasauli is a lyophilized preparation of infected mouse brain tissue. Due to this it is impossible to make it in mass quantity and as expected it is also expensive. Moreover it is only sixty percent efficacious even after multiple boosters. Dr Basu also noted that multiple boosters not only makes it further expensive but also makes the treatment regime difficult, especially for the follow-up booster doses. It is also noteworthy to mention that at least in India prevalence of JE is predominantly observed in rural/remote and socio economically backward parts of the country. As there are multiple pockets of JE epidemic persists in the country, sometimes it is logistically difficult to transport vaccines in larger quantities from CRI to the location of epidemic. On the other hand minocycline, a tetracycline is easily available in pharmacy or in a primary health care center, in even very rural and remote set up and it is also inexpensive.

This study has shed more light on the processes that lead to death in children infected with JE virus" Dr Basu said. "We hope that these discoveries will lead to new treatments for JE, which remains a leading cause of death due to encephalitis in entire Asia-Pacific region. Department of Biotechnology is actively considering a clinical trial to use minocycline for JE patients. In addition to Dr Basu, Manoj Kumar Mishra a graduate student of NBRC is also involved in this study. This study is funded by Council of Scientific and Industrial Research, and NBRC is funded by Department of Biotechnology.


'/>"/>

Contact: Melanie Thomson
melanie.thomson@oxon.blackwellpublishing.com
01-865-476-270
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... MAP Health ... this year’s Fierce Innovation Awards: Healthcare Edition 2017, an awards program from the ... of Population Health Management/Patient Engagement Solutions. , MAP was selected as a ...
(Date:7/27/2017)... , ... July 27, 2017 , ... Cremations recently surpassed ... Funeral Directors Association, this trend is expected to continue with over 70% of Americans ... a growing demand for new innovations that enable families to celebrate the life of ...
(Date:7/26/2017)... Miami, FL (PRWEB) , ... July 26, 2017 , ... ... caps that treat hereditary hair loss. The new Flexible Fitting Design offers a more ... of Capillus, LLC is delighted with the improvements to the home-use laser therapy caps ...
(Date:7/26/2017)... Madison, WI (PRWEB) , ... July 26, 2017 ... ... launch of Talent Management Solutions as part of their continued efforts to provide ... retain, and develop the best IT resources and build dynamic, high-performing teams to ...
(Date:7/26/2017)... PA (PRWEB) , ... July 26, 2017 , ... “We ... said Dr. Ahmed Mauassra, from San Jose, Calif., “so we invented the MAGNETIC/ LOCK ... the bracket portion of orthodontic braces. In doing so, it offers an effective alternative ...
Breaking Medicine News(10 mins):
(Date:7/24/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO ... quarter 2017 operating results on Monday, August 7, 2017 ... at 5:00 p.m. ET. ... live broadcast of the conference call by dialing 877-201-0168 ... 51641230 approximately 15 minutes prior to the call. A ...
(Date:7/21/2017)... 21, 2017 Did you know that PhRMA member companies ... that combined spending on brand medicines, generics and the supply chain ... accounting for just half of this (7 percent)? Or that ... the world,s venture capital investments in high-growth biopharmaceutical startups? ... ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology: